Factory/PlantPharma & medical

Kobayashi Pharmaceutical starts operations at new Sendai pharmaceutical plant in Miyagi

Kobayashi Pharmaceutical Co., Ltd.Taiwa, MiyagiPublished Jul 19, 2026

Investment¥26B

PhaseCompleted

Start—

CompletionMar 26, 2026

Kobayashi Pharmaceutical's wholly-owned subsidiary Sendai Kobayashi Pharmaceutical has begun full operation of a new pharmaceutical plant at the Sendai Kita Core Industrial Park in Taiwa-cho, Miyagi Prefecture. The facility, built to PIC/S GMP international standards with an investment of about JPY 26 billion, will produce liquid bandages, eye drops, and topical anti-inflammatory products, with total annual capacity of about 35 million units across all products.

Project facts

Owner: Kobayashi Pharmaceutical Co., Ltd.
Listing: 4967 Tokyo
Facility: Factory/Plant
Sector: Pharma & medical
Location: Taiwa, Miyagi, Japan
Investment: ¥26B — total
Scale / capacity: approx. 35 million units per year (all products combined)
Completion: Mar 26, 2026
Announced: Apr 17, 2026
Themes: reshoring

Figures and schedules are as announced by the company or the public body concerned; plans can change. Amounts that were not disclosed are recorded as not disclosed, never estimated.

Also in Miyagi4 projects · ¥426B disclosedOn the map →

Fantasista to develop 200MW AI data center in SendaiFantasista Co., Ltd.Planned¥400B Tokyo Tatemono completes T-LOGI Sendai multi-tenant logistics facilityTokyo Tatemono Co., Ltd.Completedn/d Getworks and Tohoku Electric Power complete container-type 'Miyagi AI Data Center' in ShichigahamaGetworks Co., Ltd.Completedn/d

Latest in Pharma & medicalAll Pharma & medical →

Fujifilm to install ADC raw-material manufacturing equipment at Hirono plant

NewPharma & medicalFukushimaPlanned2026.10.07

Fujifilm will install payload and linker-payload manufacturing equipment, including reaction vessels, a filtration dryer and a preparative HPLC system, at the Hirono plant in Fukushima. The facility will also add a laboratory for process and analytical-method development, with operations scheduled to begin in 2028, enabling Fujifilm's one-stop domestic ADC CDMO service.

Shikoku Chuken to build new headquarters and research facility in Ayagawa

Pharma & medicalKagawaPlanned2026.10.01

Shikoku Chuken will build a new headquarters facility on land adjacent to its existing headquarters in Ayagawa, Kagawa. The facility will expand research and development using clinical specimens and testing data collected from across Shikoku, along with corporate planning, information processing and administrative functions; operations are scheduled to begin in January 2028.

Olympus completes new B Building at Nagano site for medical-device component production

Pharma & medicalNaganoCompleted¥18B2026.08.21

Olympus has completed the new B Building at its Nagano site in Tatsuno, Nagano, consolidating development and manufacturing functions and establishing a production base for key medical-device components. Construction began in February 2025, with full operation targeted for FY2026; the building has 17,665 sqm of total floor area and a total construction cost of approximately ¥18 billion.

JGC completes Chugai Pharma's UT3 biopharmaceutical API facility in Utsunomiya

Pharma & medicalTochigiCompleted2026.08.17

JGC Holdings completed the UT3 biopharmaceutical active pharmaceutical ingredient facility for Chugai Pharmaceutical Industry at its Utsunomiya plant in May 2026. The four-story facility supports clinical-trial manufacturing through initial commercial production and includes continuous-production capabilities, solar panels and other environmental features; it was handed over on May 14, 2026.